POMC and LEPR deficiency trials
Two single-arm, open-label phase 3 trials enrolled 10 people with POMC deficiency and 11 with LEPR deficiency. At about one year, 8 of 10 (80%) and 5 of 11 (45%) had lost at least 10% of body weight, and the hunger score fell by about 27% (POMC) and 44% (LEPR) in the 7 people per trial whose hunger scores were analysed. No serious treatment-related adverse events were reported. Injection-site reactions occurred in all participants, and all 10 people with POMC deficiency had skin pigmentation changes.
- Study type
- Human trial
- Population
- 10 people with POMC deficiency and 11 with LEPR deficiency; 10 hospitals; single-arm, open-label phase 3.
- Source
- 1 Clement et al., 2020
Limitation: Two very small trials with no control group, in ultra-rare conditions.
Limitations in full
Two very small trials with no control group, in ultra-rare conditions. The hunger result covers only 7 people per trial. Results come from open-label use, so people knew they were on treatment.